Gilead Sciences (GILD) Change in Taxes (2009 - 2026)
Gilead Sciences' (GILD) quarterly Change in Taxes came in at -$29.0 million in Q1 2026, up 94.75% YoY from -$14.9 million in Q1 2025, and up 78.36% on a QoQ basis from -$134.0 million in Q4 2025.
Gilead Sciences (GILD) Change in Taxes (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Change in Taxes data on file, last reported at -$29.0 million in Q1 2026.
- Quarterly Change in Taxes rose 94.75% year-over-year to -$29.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 billion (down 47.3% YoY) and the FY2025 annual result came in at -$2.1 billion, down 187.98% from the prior year.
- Change in Taxes grew to -$29.0 million in Q1 2026, from -$134.0 million in the prior quarter.
- In the past five years, Change in Taxes ranged from a high of $536.0 million in Q4 2024 to a low of -$1.3 billion in Q2 2025.
- A 5-year average of -$294.2 million and a median of -$134.0 million in 2025 frame the typical range for Change in Taxes.
- The widest YoY moves for Change in Taxes: up 176.79% in 2024, down 4082.14% in 2024.
- Tracing GILD's Change in Taxes over 5 years: stood at $119.0 million in 2022, then slumped by 686.55% to -$698.0 million in 2023, then soared by 176.79% to $536.0 million in 2024, then tumbled by 125.0% to -$134.0 million in 2025, then jumped by 78.36% to -$29.0 million in 2026.
- The last three Change in Taxes figures came in at -$29.0 million (Q1 2026), -$134.0 million (Q4 2025), and -$122.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.22 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -131.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 171.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 171.00 Mn |
| Jun 30, 2026 | 171.00 Mn |
| Mar 31, 2026 | -29.00 Mn |
| Mar 31, 2026 | -29.00 Mn |
| Dec 31, 2025 | -134.00 Mn |
| Dec 31, 2025 | -134.00 Mn |
| Sep 30, 2025 | -122.00 Mn |
| Sep 30, 2025 | -122.00 Mn |
| Jun 30, 2025 | -1.30 Bn |
| Jun 30, 2025 | -1.30 Bn |
| Mar 31, 2025 | -552.00 Mn |
| Mar 31, 2025 | -552.00 Mn |
| Dec 31, 2024 | 536.00 Mn |
| Dec 31, 2024 | 536.00 Mn |
| Sep 30, 2024 | 111.00 Mn |
| Sep 30, 2024 | 111.00 Mn |
| Jun 30, 2024 | -1.17 Bn |
| Jun 30, 2024 | -1.17 Bn |
| Mar 31, 2024 | -208.00 Mn |
| Mar 31, 2024 | -208.00 Mn |